The cytotoxic T lymphocyte associated protein 4 (CTLA-4) gene 
Myasthenia gravis (MG) is considered a prototype for auto antibody-mediated autoimmune diseases. Autoantibodies against the nicotinic acetylcholine receptors (AChR) on the motor end plates of skeletal muscles disturb receptor function, leading to muscle weakness and fatigability. Thymic abnormalities are common in MG. Thymic hyperplasia is frequently found in female patients with early onset of the disease while thymoma occurs in patients with late onset of the disease. Patients with thymoma generally have a severe disease and often inflammatory infiltrates of the skeletal muscles. They typically show a poor response to thymectomy and often need immunosuppressive treatment.
The cytotoxic T lymphocyte associated protein 4 (CTLA-4) is a receptor mainly displayed on activated T cells. CTLA-4 plays a critical role in down regulating immune responses. Polymorphisms of the CTLA-4 gene (Ctla-4) that affect the function or the expression of the protein could thus have implications for the immune response. Mice who lack the (Ctla-4 develop a lethal phenotype with massive T cell activation and T cell infiltrates in virtually all organs.
1 Three Ctla-4 polymorphisms have been described: a single nucleotide polymorphism (SNP) in the promoter region (cytosine (C) or thymine (T)) at position −318, 2 a SNP (adenine (A) or guanine (G)) in the coding sequence (CDS) 1 at position +49, 3 and a repeat length polymorphism (AT)n at position +642 of the 3Ј-untranslated region (3Ј-UTR). 4 We have previously reported that alleles with longer PCR products than 86 bp in an (AT)n polymorphism in the 3Ј-UTR of Ctla-4 are associated with myasthenia gravis with thymoma, while the shortest allele, 86 bp, is negatively associated with the disease. 5 We have also demonstrated that the length of the (AT)n in Ctla-4 is associated with increased spontaneous T cell activity, as measured by telomerase activity and serum concentration of sIL-2R. 6 In the present study, we have investigated the two other known SNPs in Ctla-4 and their relation to MG. One hundred and one unrelated Swedish Caucasian patients and 122 ethnically matched healthy individuals were included. In the patient group, there were 39 males and 62 females. These patients were not the same as those studied in our earlier report. 5 The age of onset was under 40 in 54 patients. Fifty-six patients were thymectomized and thymic hyperplasia was present in 30, whereas 15 patients had thymomas. Eleven patients had normal thymic histopathology.
There was no difference in the promoter SNP between patients and healthy individuals ( Table 1) . Studies of other autoimmune diseases have described the T −318 allele to be less common in patients with Graves' disease and Hashimoto's thyroiditis, 7 and in patients with multiple sclerosis (MS), but more prevalent in patients with peripheral neuropathy. 8 Other studies have not verified these associations. Although this SNP occurs in the promoter region, it is unlikely to be of functional importance since it does not affect any known consensus sequence in the regulatory region of the promoter.
In addition, there was no difference in the CDS1 SNP between patients and controls. When patients were strati- Table 1 The promoter and CDS1 SNP of Ctla-4 in healthy controls (HC) and in patients with myasthenia gravis (MG) and different thymic histopathology. The Ctla-4 promoter SNP at position −318 and the CDS1 SNP at position +49 were defined using a polymerase chain reaction (PCR) as described, fied according to thymic histopathology, patients with thymoma had more often allele G and genotype G/G at position +49 in CDS1 than patients with thymic hyperplasia and patients with normal thymic histopathology ( Table 1) . A higher prevalence of the G allele was described in SLE, 9 rheumatoid arthritis, 10 type 1 diabetes, 11 primary biliary cirrhosis, 12 multiple sclerosis 13 and Graves' disease. 14 Other studies have failed to confirm these results. The A/G SNP results in an amino acid exchange (Thr to Ala) in the leader sequence. It was recently described that carriage of the G allele reduces the inhibitory function of CTLA-4 and thus contributes to the pathogenesis of Graves' disease. 15 Thus, we might hypothesize that the G allele may contribute to the disease expression in certain forms of MG, notably in older patients with thymomas, who have no distinct HLAassociation and usually a severe disease with an inflammatory component.
The distribution of the combined alleles of CDS1 and A: Adenine; CDS: coding sequence.
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promoter SNPs did not differ between patients and healthy individuals. There was no patient or healthy individual who carried the T allele (promoter −318) and was homozygous for the G allele of CDS1. The linkage disequilibrium between the promoter and the CDS1 SNP was estimated by calculation of delta values (⌬) based on the observed and expected haplotype frequencies. 16 There were positive linkages between C (promoter −318) and G (CDS1) (⌬ = 0.037, P = 0.0436) and T and A (⌬ = 0.014, P = 0.0436) in patients and healthy individuals. + cells in patients with myasthenia gravis (MG), using a FACSCalibur flow cytometer and FITC or PE conjugated mAb (CD3-FITC, CD28-PE, HLA-DR-PE from Pharmingen, San Diego, CA, USA). The percentage of CD28
+ cells differed between patients with different genotypes (P Ͻ 0.001).
Figure 2
Levels of IL-1␤ and IL-12 were analysed using a sandwich ELISA (R&D system, Oxon, UK). Antibodies against the acetylcholine receptor (AChR) were analysed by radioimmunoassay. 18 The level of IL-1␤ (a) is related to the genotypes at position 49 + in the CDS1 region of Ctla-4 (P Ͻ 0.05). There were no associations with IL-12 (b) and anti-AChR (c) levels.
There was no difference between patients and healthy individuals in the distribution of the various genotypes when combining the Ctla-4 3Ј-UTR polymorphism with promoter and CDS1 SNPs. Calculation of the delta value revealed linkage disequilibrium between the A allele in the CDS1 and the 86 microsatellite marker in the 3Ј-UTR region in healthy individuals (⌬ = 0.166, P Ͻ 0.0001) and also in patients with MG (⌬ = 0.121, P = 0.0005). Linkage of the G allele in CDS1 and alleles Ͼ86 bp long in the 3Ј-UTR microsatellite marker was present in healthy individuals (⌬ = 0.085, P Ͻ 0.0001) and in patients with MG (⌬ = 0.061, P = 0.0005) ( Table 2) .
Thus, there is a clear genetic linkage between the three polymorphisms in the Ctla-4. In this report we found that the A allele in CDS1 is in strong linkage with the shortest 86 bp allele in the 3Ј-UTR. We could also confirm the finding that the T allele of the promoter region was in strong linkage with the A allele of CDS1. 7, 17 This indicates that the A/G SNP has been more conserved during evolution than the promoter SNP and the 3Ј-UTR polymorphism.
When studying the expression of the T lymphocyte activation markers CD28 and HLA-DR, we found that the percentage of T cells bearing CD28 was higher in patients with the G/G genotype in CDS1 than in those bearing genotypes A/A or A/G (P Ͻ 0.001) (Figure 1) . Patients with the G/G genotype in CDS1 had also higher serum levels of IL-1␤ (P Ͻ 0.05) (Figure 2 ). There was no difference in the concentrations of AChR-antibodies and IL-12 in serum from patients with different genotypes ( Figure  2) .
In Summary, Ctla-4 promoter and CDS1 SNPs and the (AT)n polymorphism in the 3Ј-UTR were analysed in Swedish MG patients. Patients with thymoma had a higher frequency of the G allele and the G/G genotype at position +49 in CDS1 than patients with normal or hyperplastic thymic histopathology. The G/G genotype was also associated to immune activation as manifested by higher levels of serum IL-1␤ and higher percentage of CD28-positive T lymphocytes. Our results suggest that the SNP at position +49 in CDS1 may be associated to the manifestations of certain forms of MG.
